Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Calcipotriene. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR known ✓ | P11473 | 13/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 3/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 2/20 | 1.00 |
| ▸ | PGR | P06401 | 2/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 2/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 2/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 2/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.67 |
| ▸ | CYP24A1 | Q07973 | 2/20 | 0.65 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.64 |
| ▸ | GC | P02774 | 1/20 | 0.64 |
| ▸ | RXRA | P19793 | 1/20 | 0.64 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.64 |
| ▸ | CNR1 | P21554 | 1/20 | 0.64 |
| ▸ | HTR2C | P28335 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Calcipotriene SCHEMBL3278756 | 1.00 | VDR (1.00) | VDRADORA3SLC6A2NR1I2PGR | |
| Calcipotriene SCHEMBL12311926 | 1.00 | VDR (1.00) | VDRADORA3SLC6A2NR1I2PGR | |
| Calcipotriene SCHEMBL21849105 | 1.00 | VDR (1.00) | VDRADORA3SLC6A2NR1I2PGR | |
| Calcipotriene SCHEMBL13044528 | 1.00 | VDR (1.00) | VDRADORA3SLC6A2NR1I2PGR | |
| Calcipotriene SCHEMBL24066882 | 1.00 | VDR (1.00) | VDRADORA3SLC6A2NR1I2PGR | |
| Calcipotriene SCHEMBL2455296 | 1.00 | VDR (1.00) | VDRADORA3SLC6A2NR1I2PGR | |
| Calcipotriene SCHEMBL23339038 | 1.00 | VDR (1.00) | VDRADORA3SLC6A2NR1I2PGR | |
| Calcipotriene SCHEMBL22364326 | 1.00 | VDR (1.00) | VDRADORA3SLC6A2NR1I2PGR | |
| Calcipotriene SCHEMBL22364325 | 1.00 | VDR (1.00) | VDRADORA3SLC6A2NR1I2PGR | |
| Calcipotriene SCHEMBL22364327 | 1.00 | VDR (1.00) | VDRADORA3SLC6A2NR1I2PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 23975 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12636262-B2 | Process for the preparation of topical formulation | Neuheit Pharma Technologies Pvt. Ltd. (IN) | 2026-05-26 | — | — | US | claimed |
| US-20260138973-A1 | SUBSTITUTED PYRIDINES FOR USE IN TREATING OR PREVENTING INFLAMMATORY DISEASES OR DISEASES ASSOCIATED WITH AN UNDESIRABLE IMMUNE RESPONSE | SITRYX THERAPEUTICS LTD (GB) | 2026-05-21 | — | — | US | claimed |
| US-20260137680-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LTD (GB) | 2026-05-21 | — | — | US | claimed |
| CN-122028909-A | Lipid nanoparticles with non-covalent bifunctional conjugates for active targeting | 莫特治疗股份有限公司 | 2026-05-12 | — | — | CN | claimed |
| US-12616749-B2 | Methods for treatment of psoriasis with an anti-oxLDL antibody | ABCENTRA, LLC (US) | 2026-05-05 | — | — | US | claimed |
| US-20260115324-A1 | Chimeric Antigen Receptors Targeting CD19 | ORNA THERAPEUTICS, INC. (US) | 2026-04-30 | — | — | US | claimed |
| US-20260115228-A1 | Chimeric Antigen Receptors Targeting CD19 | ORNA THERAPEUTICS, INC. (US) | 2026-04-30 | — | — | US | claimed |
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-04-30 | — | — | US | claimed |
| EP-4731606-A1 | IONIZABLE THIOLIPIDS AND USES THEREOF | BioNTech SE (DE) | 2026-04-29 | — | — | EP | claimed |
| US-20260092050-A1 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | RAPT THERAPEUTICS INC (US) | 2026-04-02 | — | — | US | claimed |
| EP-0679154-B1 | NEW CRYSTALLINE FORM OF A VITAMIN D ANALOGUE | LEO PHARM PROD LTD (DK) | 1997-10-29 | — | — | EP | claimed |
| EP-0758233-A1 | PDE IV INHIBITORS FOR TREATING MULTIPLE SCLEROSIS | SCHERING AKTIENGESELLSCHAFT (DE) | 1997-02-19 | — | — | EP | claimed |
| WO-1996026711-A1 | NITRIC OXIDE SYNTHASE INHIBITORS | L'OREAL (FR) | 1996-09-06 | — | — | WO | claimed |
| EP-0714304-A1 | THERAPEUTIC SYSTEM FOR TREATING PSORIASIS | LTS Lohmann Therapie-Systeme GmbH & Co. KG (DE) | 1996-06-05 | — | — | EP | claimed |
| WO-1996014048-A1 | TREATMENT OF KERATINIC AND PSORIATIC DISORDERS WITH A NAIL LACQUER CONTAINING A VITAMIN D METABOLITE OR DERIVATIVE AND/OR A VITAMIN A DERIVATIVE | SEIDENSCHNUR EDEL K (DK) | 1996-05-17 | — | — | WO | claimed |
| WO-1996000074-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING VITAMIN-D ANALOGS | BEN-GURION UNIVERSITY OF THE NEGEV (IL) | 1996-01-04 | — | — | WO | claimed |
| WO-1995028926-A1 | PDE IV INHIBITORS FOR TREATING MULTIPLE SCLEROSIS | SCHERING AKTIENGESELLSCHAFT (DE) | 1995-11-02 | — | — | WO | claimed |
| WO-1995005829-A1 | THERAPEUTIC SYSTEM FOR TREATING PSORIASIS | LTS LOHMANN THERAPIE-SYSTEME GMBH & CO. KG (DE) | 1995-03-02 | — | — | WO | claimed |
| US-5292727-A | Administering calcipotriol | LEO PHARMACEUTICAL PRODUCTS LTD. (DK) | 1994-03-08 | — | — | US | claimed |
| EP-0544391-A1 | Compositions for topical treatment of psoriasis and atopic dermatitis | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1993-06-02 | — | — | EP | claimed |